HRA005873
Title:
A Randomized, Double-Blind, Multicenter, Phase III Clinical Study of HLX10 + Chemotherapy vs Chemotherapy as First-Line Therapy for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Release date:
2023-10-29
Description:
Global common Screen 809,Randomized 537,In Treatment 41,In survival follow up 99,End of Study 397.genetic raw data of TMB/MSI testing.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
lung squamous cell carcinoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
Shanghai Henlius Biotech,Inc.
Contact person:
Li Rui
Email:
Rui_Li@henlius.com
Description:
An international and innovative biopharmaceutical company
Individuals & samples
Submitter:   Ren Shengxiang / shengxiang_ren2023@163.com
Organization:   Shanghai Pulmonary Hospital
Submission date:   2023-10-23
Requests:   -